Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds

Jinhui Zhang, Lei Wang, Guangxun Li, Lorraine B. Anderson, Yanji Xu, Bruce Witthuhn, Junxuan Lu

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We have shown that, in contrast to selenomethionine (SeMet) or selenite, methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) exert prostate cancer (PCa) inhibitory effect in preclinical models. Here we investigated the prostate proteome signatures of mice treated with each selenium (Se) form for hypothesis generation concerning their potential in vivo molecular targets and cancer risk modification. Nude mice bearing subcutaneous PC-3 xenografts were treated daily with each Se form (3 mg Se/kg) orally for 45 days. Five prostates were pooled from each group. Their proteomes were profiled by LC-MS/MS with iTRAQ labeling. Of the 1,088 proteins identified, 72 were significantly modulated by one or more Se forms. MSeA and MSeC each induced separate sets of tumor suppressor proteins and suppressed different onco-proteins. Proteins induced by selenite and shared with MSeC were related to energy metabolism (e.g., fatty-acid synthase), and those induced by SeMet included vimentin and heat-shock protein-70, favoring cancer growth. While proteome changes induced by MSeA were associated with PCa risk reduction, desirable risk-reducing signatures induced by MSeC were counterbalanced by risk-promoting patterns shared with selenite and SeMet. We propose that the balance of oncogenic vs. suppressor protein patterns in the prostate may impact the direction of PCa risk modification by a given selenium.

Original languageEnglish (US)
Pages (from-to)778-789
Number of pages12
JournalNutrition and cancer
Volume63
Issue number5
DOIs
StatePublished - Jul 1 2011

Fingerprint

Selenium Compounds
Proteome
Selenium
Prostate
Selenomethionine
Selenious Acid
Prostatic Neoplasms
Proteins
Tumor Suppressor Proteins
Fatty Acid Synthases
HSP70 Heat-Shock Proteins
Vimentin
Risk Reduction Behavior
Heterografts
Nude Mice
Energy Metabolism
Neoplasms
selenomethylselenocysteine
Growth

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Oncology
  • Nutrition and Dietetics
  • Cancer Research

Cite this

Zhang, Jinhui ; Wang, Lei ; Li, Guangxun ; Anderson, Lorraine B. ; Xu, Yanji ; Witthuhn, Bruce ; Lu, Junxuan. / Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. In: Nutrition and cancer. 2011 ; Vol. 63, No. 5. pp. 778-789.
@article{7ca4cc9d500746b98b8fd875bcd955d9,
title = "Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds",
abstract = "We have shown that, in contrast to selenomethionine (SeMet) or selenite, methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) exert prostate cancer (PCa) inhibitory effect in preclinical models. Here we investigated the prostate proteome signatures of mice treated with each selenium (Se) form for hypothesis generation concerning their potential in vivo molecular targets and cancer risk modification. Nude mice bearing subcutaneous PC-3 xenografts were treated daily with each Se form (3 mg Se/kg) orally for 45 days. Five prostates were pooled from each group. Their proteomes were profiled by LC-MS/MS with iTRAQ labeling. Of the 1,088 proteins identified, 72 were significantly modulated by one or more Se forms. MSeA and MSeC each induced separate sets of tumor suppressor proteins and suppressed different onco-proteins. Proteins induced by selenite and shared with MSeC were related to energy metabolism (e.g., fatty-acid synthase), and those induced by SeMet included vimentin and heat-shock protein-70, favoring cancer growth. While proteome changes induced by MSeA were associated with PCa risk reduction, desirable risk-reducing signatures induced by MSeC were counterbalanced by risk-promoting patterns shared with selenite and SeMet. We propose that the balance of oncogenic vs. suppressor protein patterns in the prostate may impact the direction of PCa risk modification by a given selenium.",
author = "Jinhui Zhang and Lei Wang and Guangxun Li and Anderson, {Lorraine B.} and Yanji Xu and Bruce Witthuhn and Junxuan Lu",
year = "2011",
month = "7",
day = "1",
doi = "10.1080/01635581.2011.563029",
language = "English (US)",
volume = "63",
pages = "778--789",
journal = "Nutrition and Cancer",
issn = "0163-5581",
publisher = "Routledge",
number = "5",

}

Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds. / Zhang, Jinhui; Wang, Lei; Li, Guangxun; Anderson, Lorraine B.; Xu, Yanji; Witthuhn, Bruce; Lu, Junxuan.

In: Nutrition and cancer, Vol. 63, No. 5, 01.07.2011, p. 778-789.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mouse prostate proteomes are differentially altered by supranutritional intake of four selenium compounds

AU - Zhang, Jinhui

AU - Wang, Lei

AU - Li, Guangxun

AU - Anderson, Lorraine B.

AU - Xu, Yanji

AU - Witthuhn, Bruce

AU - Lu, Junxuan

PY - 2011/7/1

Y1 - 2011/7/1

N2 - We have shown that, in contrast to selenomethionine (SeMet) or selenite, methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) exert prostate cancer (PCa) inhibitory effect in preclinical models. Here we investigated the prostate proteome signatures of mice treated with each selenium (Se) form for hypothesis generation concerning their potential in vivo molecular targets and cancer risk modification. Nude mice bearing subcutaneous PC-3 xenografts were treated daily with each Se form (3 mg Se/kg) orally for 45 days. Five prostates were pooled from each group. Their proteomes were profiled by LC-MS/MS with iTRAQ labeling. Of the 1,088 proteins identified, 72 were significantly modulated by one or more Se forms. MSeA and MSeC each induced separate sets of tumor suppressor proteins and suppressed different onco-proteins. Proteins induced by selenite and shared with MSeC were related to energy metabolism (e.g., fatty-acid synthase), and those induced by SeMet included vimentin and heat-shock protein-70, favoring cancer growth. While proteome changes induced by MSeA were associated with PCa risk reduction, desirable risk-reducing signatures induced by MSeC were counterbalanced by risk-promoting patterns shared with selenite and SeMet. We propose that the balance of oncogenic vs. suppressor protein patterns in the prostate may impact the direction of PCa risk modification by a given selenium.

AB - We have shown that, in contrast to selenomethionine (SeMet) or selenite, methylseleninic acid (MSeA) and Se-methylselenocysteine (MSeC) exert prostate cancer (PCa) inhibitory effect in preclinical models. Here we investigated the prostate proteome signatures of mice treated with each selenium (Se) form for hypothesis generation concerning their potential in vivo molecular targets and cancer risk modification. Nude mice bearing subcutaneous PC-3 xenografts were treated daily with each Se form (3 mg Se/kg) orally for 45 days. Five prostates were pooled from each group. Their proteomes were profiled by LC-MS/MS with iTRAQ labeling. Of the 1,088 proteins identified, 72 were significantly modulated by one or more Se forms. MSeA and MSeC each induced separate sets of tumor suppressor proteins and suppressed different onco-proteins. Proteins induced by selenite and shared with MSeC were related to energy metabolism (e.g., fatty-acid synthase), and those induced by SeMet included vimentin and heat-shock protein-70, favoring cancer growth. While proteome changes induced by MSeA were associated with PCa risk reduction, desirable risk-reducing signatures induced by MSeC were counterbalanced by risk-promoting patterns shared with selenite and SeMet. We propose that the balance of oncogenic vs. suppressor protein patterns in the prostate may impact the direction of PCa risk modification by a given selenium.

UR - http://www.scopus.com/inward/record.url?scp=79960618293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960618293&partnerID=8YFLogxK

U2 - 10.1080/01635581.2011.563029

DO - 10.1080/01635581.2011.563029

M3 - Article

C2 - 21614726

AN - SCOPUS:79960618293

VL - 63

SP - 778

EP - 789

JO - Nutrition and Cancer

JF - Nutrition and Cancer

SN - 0163-5581

IS - 5

ER -